Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody

BACKGROUND: Ideally, monoclonal antibodies provide selective treatment by targeting the tumour, without affecting normal tissues. Therefore, antibody imaging is of interest, preferably in early stages of drug development. However, the imaging signal consists of specific, as well as non-specific, upt...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:EJNMMI Res
Autors principals: Jauw, Yvonne W. S., Huisman, Marc C., Nayak, Tapan K., Vugts, Danielle J., Christen, Randolph, Naegelen, Valerie Meresse, Ruettinger, Dominik, Heil, Florian, Lammertsma, Adriaan A., Verheul, Henk M. W., Hoekstra, Otto S., van Dongen, Guus A. M. S., Menke-van der Houven van Oordt, C. Willemien
Format: Artigo
Idioma:Inglês
Publicat: Springer Berlin Heidelberg 2018
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5778091/
https://ncbi.nlm.nih.gov/pubmed/29356983
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13550-018-0358-8
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars